A Tata memorial centre led study concludes that 50% oral cancer patients die within a year of diagnosis

INDIA – The first-of-its-kind study on the ‘cost of illness analysis of oral cancer’, conducted by Tata Memorial Centre in Mumbai, reveals that half of oral cancer patients in India die within a year of diagnosis and are aged between 30-50 years. The study was conducted on 100 consecutive oral cancer patients who sought treatment at the facility between October 2019 and March 2020 and pointed out that most of the patients who receive some form of treatment are left unemployed hence they become an economic burden to their families.…

Read More

Boehringer Ingelheim’s Pradaxa approved by the FDA for oral pediatric use

USA – The Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Pradaxa as the first oral blood thinning medication suitable for children 12 years and below in the USA. The medication Pradaxa will be available for use for children with venous thromboembolism immediately after treatment with a blood thinner given by injection for at least five days. Venous thromboembolism (VTE) is a disorder that includes deep vein thrombosis and pulmonary embolism with deep vein thrombosis (DVT) occurring when a blood clot forms in a deep vein, usually in the…

Read More

Bayer’s Astepro approved for over the counter use in the US

US – The US Food and Drug Administration (FDA) has approved Bayer’s steroid-free antihistamine nasal spray Astepro for over-the-counter use. Astepro becomes the first and only OTC steroid-free antihistamine nasal spray available in the US for adults and children aged six years and older. Currently, OTC allergy medications is classified into three major classes which include antihistamines, intranasal steroids and mast cell stabilizers. Bayer, a German multinational pharmaceutical and life sciences company had astepro previously approved for prescription use in 2008. Following the approval by the FDA, Astepro will be…

Read More

India’s pharmaceutical pricing authority issues new guidelines on pricing of drugs

INDIA -The Nationwide Pharmaceutical Pricing Authority (NPPA) has directed all producers and advertising firms of medication, formulations and medical gadgets to cut back costs of merchandise already available in the market NPPA has asked all producers and advertisers to revise their utmost retail cost of medications on which Goods and Service Tax (GST) have been diminished. The regulatory body has requested the involved parties to recall, relabel products of launched shares available in the market in order to have them meet the regulatory compliance. Producers will be made accountable for…

Read More

The Obamacare upheld by the Supreme court following the republicans bid to overturn it

US – The US Supreme Court has rejected a bid by Republican-led states to overturn Obamacare, safeguarding the health insurance of millions at a time when the COVID-19 is still a threat in much of America. The 7-2 ruling decision by the supreme court upheld the Affordable Care Act with Texas and 17 other states not having a stand in the case. The Affordable Care Act (ACA) is the comprehensive healthcare reform signed into law by President Barack Obama in March 2010 and is known as the Patient Protection and…

Read More

Joseph Biden’s administration pumps in US$3.2bn for the development of a COVID-19 drug

US – The US government is taking another leap into the fight against COVID-19 through an investment worth US$3.2 billion to help develop antiviral therapy pills. This is part of the American Rescue Plan (ARP) government strategy to develop the next generation of COVID-19 treatments. ARP was developed to provide emergency grants, lending, and investment to hard-hit small businesses during the pandemic. This plan will provide more than $300 million for research and lab support, nearly $1 billion for preclinical and clinical evaluation, and nearly $700 million for development and…

Read More

Ministry embarks on a mechanism to strengthen accountability for donated blood in the Country

KENYA – The Ministry of Health, through the Kenya National Blood Transfusion Service has embarked on strengthening blood accountability mechanism, an approach that will ensure regular blood stock taking, maintenance of the national blood inventory management system and electronic tracking of donated blood. Speaking in Nairobi when she officiated the World Blood Donor Day, Health Principal Secretary, Susan Mochache, noted that the safety of blood being offered to Kenya is very important and informed that the Ministry has issued a circular on hemovigilance to ensure safety of blood. “We urge…

Read More

German legislature approves legislation that will expedite access to life-changing cell and gene therapies

GERMANY-The German parliament, the Bundestag, has approved a legislation that would enable patients have greater access to new transformative cell and gene therapies. The legislation will address a bureaucratic barrier that delayed the availabilities of new and innovative drugs, medical devices and procedures (NUB) to patients. In order to be able to integrate new examination and treatment methods into the G-DRG system, the NUB request procedure was first introduced in Germany in 2005. For this purpose, NUB requests (InEK) would only be made once in a year with the extra…

Read More

G7 summit outlines health pact to stop future pandemics

ENGLAND – G7 leaders are on Saturday set to agree a joint declaration aimed at preventing another pandemic, as they resume wide-ranging talks at their first in-person summit in almost two years. The group of leading economies — Britain, Canada, France, Germany, Italy, Japan and the United States — will also try to showcase Western democratic cohesion against a resurgent China and recalcitrant Russia. They will be joined by the leaders of Australia, South Africa and South Korea, along with India taking part remotely, as the agenda broadens to foreign…

Read More

Controversy surrounding Biogen’s newly approved Alzheimer’s drug costs FDA one more panelist

USA – A third member of a key Food and Drug Administration advisory panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm. Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School, said in his resignation letter that the agency’s decision on Biogen is probably the worst drug approval decision in recent U.S. history. “At the last minute, the agency switched its review to the Accelerated Approval pathway based on the debatable premise that the drug’s effect on brain amyloid was likely to…

Read More